Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

The U.S. FDA has granted Precision Biosciences Inc.’s PBGENE-DMD orphan drug designation for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD uses two complementary Arcus nucleases ...

Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Welcome to this week's Chutes & Ladders, our roundup | Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar ...

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July ...

The company will utilize the funds to accelerate the development of its clinical diagnostic platform and expand its ...

Complex regions of the human genome remained uncharted, even after researchers sequenced the genome in its entirety. That is, ...

One Biosciences has raised €15 million to scale its OneMap™ AI‑powered single‑cell tumour profiling platform for routine ...

Spatial proteomics continues to transform biomedical research in understanding disease progression and therapeutic response.